It is believed that CTLA-4 impacts on the stage of T-cell activation mainly in the draining lymph nodes by removing CD80/CD86 from the surface of antigen-presenting cells, thus decreasing the ability to effectively stimulate tumor-specific T cells. The gene discussed is CD80; the disease is neoplasm.